total return/p among highest group eliqui continu grow robustli
still formid player io given opdivo strong posit sever tumor
celgen acquisit bring opportun also risk await greater visibl
better read io combo
ep estim revenu growth expect
opdivo sale increas even stronger gain yervoy
eliqui look revenu growth ep growth
assum celgen acquisit effect ep growth
forecast driven cost synergi timing/ext revlimid gener
pressur reduc visibl estim revenu compound-annual-growth-rate ep compound-annual-growth-rate
well group averag
earli januari announc plan acquisit celgen stock/cash
plu celgen debt expect close late extens initi
close target due subsequ ftc requir divestitur celgen otezla
acquir celgen add strateg asset oncolog hematolog
revlimid multipl myeloma sale y/i appear pois
growth estim sale peak face gener pressur patent expir
key product includ pomalyst myeloma abraxan chemo
celgen also five near-term launch tap luspatercept liso-cel fedratinib
ozanimod along project compani
potenti revenu
face competit pressur keytruda /- chemo roch tecentriq
lung partial off-set pressur continu growth indic
melanoma renal hodgkin lymphoma bladder cancer well use adjuv
melanoma opdivo yervoy met os nsclc full data
near-term growth expect slow substanti opdivo yervoy still
could disrupt potenti lung tumor estim opdivo revenu
expand
adjuvant/neoadjuv use inhibitor could transform treatment cancer
opdivo keytruda alreadi made inroad adjuv melanoma
approxim trial way third phase
eliqui share ramp juli august overtak
xarelto lead anti-thrombot agent indic dvt pe
treatment prevent recurr dvt pe broaden usag eliqui sale
forecast
pleas see page report import disclosur
earli januari announc plan acquisit celgen celg
stock cash plu conting valu right compani bring strong
current product dynam merg entiti combin basi
note six near-term product launch total potenti
celg signific immedi accret part due cost synergi strong
cash flow announc acceler share repurchas offer ep guidanc
longer term outlook less clear new product appear
dwarf patent expir opdivo sale estim patent
laps eliqui sale peg patent laps
revlimid estim peak sale patent laps
plan acquisit celgen financ via stock share
celg share cash celg share plu conting valu right
cvr per share cash tie approv mileston ozanimod
three must meet approv time
cvr paid date ozanimod file march pdufa
expect file file transact
time frameev data mmliso-cel celg phase data r/r dlbcl ph data esophagealopdivo yervoyful part part data nsclcregulatoryinreb fedratinib celg eu file ye celg file r/r dlbcl celg approv beta-thallesemia pdufa close ye investor eventseptemb barcelona yervoy chemo ph data neoadjuv yervoy chemo ph data ph data adjuv brentuximab vedotin ph data pomalyst/empl ph data mmopdivo /- yervoy ph data rccopdivo ph data nsclc post-chemo induct ph data adjuv melanomaopdivo relatlimabph ii data melanomaozanimodiniti phase uc data north regulatoryide-cel celg file r/r mm celg approv md pdufa approv beta-thallesemia mdsozanimod celg /eu approv rm pdufa
financ cash debt line alreadi secur subject
financ condit post-clos debt combin compani pari passu
addit plan execut asr increas form post announc sale
otezla celgen upon close repurchas portion equiti issu
close expect end pend regulatori sharehold approv
slight extens initi plan close delay due
june announc celgen otezla psoriasi divest address
ftc concern august announc pay acquir otezla
celgen proce use debt reduct bmy/celg transact
sharehold compani celgen sharehold
expect deal least accret ep first full year
gener approxim run-rat cost synergi tie sg
 manufactur also anticip free cash flow
first year post-clos support dividend payment cvr
payment de-lever intern pipelin initi futur bd
celg acquisit add strateg asset oncolog hematolog
immunology/inflamm creat balanc portfolio revlimid multipl
myeloma report sale expect grow next
year base upon label expans use combin newer therapi
start face gener pressur patent expir pomalyst
refractori myeloma sale y/i also benefit
combin use myeloma abraxan sale y/i continu post
solid sale base upon success pancreat cancer though growth abat
luspatercept modifi type ii activin receptor fusion protein trap tgf
protein involv late-stag red blood cell matur promot late-stag
erythrocyt precursor cell differenti increas rbc potenti
treat myelodysplast syndrom msd beta-thalassemia full data
phase medalist msd believ beta-th studi luspatercept
present celgen file luspatercept md beta-thalassemia
april pfufa beta-thallasemia pdufa md
manag believ luspatercept could gener md beta-th alon
without factor opportun myelofibrosi
liso-cel product consist autolog chimer antigen receptor
modifi cell car-t stem acquisit data
phase studi liso-cel cll present enrol phase
transcend studi liso-cel r/r dlbcl complet follow-up data
continu collect celgen expect need least nine month
follow-up data patient treat studi prior submit applic
health author file transplant elig dlbcl expect
ozanimod oral select receptor modul develop
inflammatori immunolog diseas ozanimod file rm
eu pdufa eu approv expect enrol
phase studi ozanimod uc expect complet phase
trial crohn initi first primari complet februari initi data
uc expect
fedratinib inreb highly-select inhibitor current develop
myelofibrosi mf inreb approv august eu
submiss expect ye fedratinib acquir januari
impact bioscienc packag expect includ new clinic data celgen
anticip drug could work patient fail jakafi substanti popul
celgen anticip
car-t therapi target bcma partnership bluebird bio
enrol pivot phase ii karmma studi patient highli refractori mm
complet file expect clinic investig
earlier line therapi advanc data second bcma-direct car-t
rrmm present
estim ep revenu assum
celgen closur effect estim opdivo revenu
estim gpm declin sg decreas increas
lead increas oper margin net non-oper incom
forecast decreas tax rate decreas
averag share count hold flat share
announc celgen acquisit januari bristol manag
issu initi guidanc ep exclud impact
celgen guidanc includ dilut divestitur uspa consum
close juli cost relat pension liabil
result bristol increas full year guidanc
compani data cowen compani
estim ep revenu includ
full year celgen key product revenu assumpt includ opdivo
revlimid eliqui estim gpm increas
reflect boost celgen high gpm off-set partial
eliqui profit share sg increas increas lead
increas oper margin model assum celgen
cost synergi net non-oper incom forecast decreas
expens due financ cost celgen acquisit tax rate
increas averag share count increas
new product continu gain traction drive top- bottom-lin growth
forecast total revenu ep
estim revenu ep impli
sale ep compound-annual-growth-rate look gross profit margin
declin year larg key time revlimid gener
avail forecast sg declin increas
 project increas year assum celgen cost
synergi year forecast net
expens declin year debt paid assum tax rate
hold share count increas annual
result bristol provid pro-forma revenu net incom project
first time project provid bar graph leav
interpret open error also project updat sinc
announc divestitur otezla extend close date bristol project
call approxim revenu net incom
approxim bristol project revenu
approxim net incom approxim
estim bristol expect sale earn grow everi year
bristol cash/equival market secur long-
term debt short-term debt estim free cf
oper minu capital-expenditure approxim increas annual
celgen add boost free cash flow suffici support debt
paydown cvr payment intern develop potenti
cowen compani
compani data cowen compani
pft salesop pft salesop pft total incom mm mm nivolumab antibodi numer datapoint upcom includ adjuv readoutshematolog revlimid pomalyst idhifa luspatercet inreb liso-cel other celgen approv spaf dvt treatment prophylaxi market share patent expir ipilimumab monoclon ab melanoma tumor immun oncolog combin use drive abatacept approv rheumatoid arthrit patent expir litig settl apotex allow launch gleevec gener like temper gener launch patent expir teva launch new emplic mani novel io target productskeytruda royalti keytruda sale retain ono sale azn final royalti azn thereafterin-lin ep versu industri averag
compani data cowen compani estim
cowen compani
cowen compani
cowen compani
cowen compani
commentsanti-infect baraclud gener launch market eu japan share gener china impact brand gener eubaraclud entecavir hepat hepat non-nuc inhibitor approv japan daklinza/sunvepra develop asunaprevir hepat approv japan china pursu eu daclatasvir hepat approv japan eu china develop plannedreyataz patent expir teva launch patent expir atazanavir once-daili proteas inhibitorazactam monobactam right sold duraatripla/sustiva franchis sustiva patent exp use patent exp settlement delay competit clipsatripla/sustiva franchis eu patent expir franchis sustiva portion sustiva/truvada qd gilead royalti inj broad spect cefepim right sold hiv ec domin gener competit barr top aminoglycosid certain right bulk penicillin mostli intern otheranti-infect approv tumor type futur differenti key nivo/ipi novel combo adjuv useopdivo slower penetr io overal adjuv offsetsopdivo nivolumab antibodi numer datapoint upcom includ adjuv readoutsorencia substanc patent exp mou patent exp management expect gener iv/sq substanc pat exp method gener expect myl/momenta biosimilar clinic fail iv/sq abatacept approv rheumatoid arthrit psasprycel patent expir litig settl apotex allow launch gleevec gener like temper growthsprycel patent exp revok pto appeal hear gener launch marketssprycel src/abl kinas inhib resist cml gi lung stromal readi trial prostat meet endpointyervoy near term pressur monotherapi melanoma abat futur key nivo comboyervoy ipilimumab monoclon ab melanoma tumor immun oncolog combin use drive protein-bound paclitaxel breast lung pancreat cancer via celgen oral select file rm us/eu pdufa piii uc piii crohn initi via celg elotuzumab approv refractori multipl myeloma line data abbvieido small molecul io target phase immunosci psoriasi small molecul phase io target biolog phase biolog phase fibrot diseas small molecul phase io target biolog phase dual small molecul phase iibtk immunosci small molecul phase manag fibrot diseas biolog phase uracil tegafur leucovorin colon cancer foreign market
cowen compani
commentscancer/immunolog continuednulojix belatacept block t-cell activ market renal transplant reject lslet transplant phase gener pressur foreign better toxic profil platinol genericsvepesid patent expir phosphat patent expir licens miscellan celgen product othercanc patent expir natco enter mid-singl volum full gener entri multipl myeloma r/r fl refractori file s/eu md pdufa beta thalassemia pdufa ph ii bcma car-t multipl myeloma file car-t ph data file r/r dlbcl ph ii r/r enasidenib r/r fedratinib highli select inhib myelofibrosi resist patient intoler jakafi approv eu file multipl azacitidin myelodysplast celgen pipelin opportunitieshematolog via celgen acquisit assum close approv spaf dvt treatment prophylaxi market share patent expir approv spaf dvt treatment prophylaxi patent expir apixaban oral factor xa inhibitor pfizerrecothromnmnm right purchas medicin compani close patent expir xia small molecul cardiovascular phase iinitroxyl heart failur small molecul phase anticoagul gener competit clipsquestran older resin cholesterol reduc over-the-counter outlook unclearplavix exclus end pediatr extensionplavix gener euplavix patent expir patent expir canada mexico argentina avapro arb gener productscardiova
cowen compani
 reflect upsa line effect older squibb productsabilifi total revenu agreement expir abilifi total revenu agreement expir eu canadaabilifi total revenu schizophrenia miscellan product genericscn potenti over-the-counter switch older product neg sale suggest heavi discountsderm gener exclus end pediatr extensionglucophag exclus end expect declin expir royalti allianc agreementstot industri averag growth over-the-counter sold taisho pharma close new drugs/celgen drive growth pro-forma suggest
race continu bristol remain lead competitor alongsid
merck given approv differ tumor type melanoma non-smal cell lung small
cell lung renal hodgkin lymphoma bladder msi-h
avail approv combin yervoy melanoma rcc well
anticip approv opdivo yervoy nsclc potenti chemo-fre
combin regimen set competit nsclc market share especi
fierc mrk keytruda current domin posit longer term potenti
opdivo yervoy induc deeper durabl respons compet io/chemo
combo may temper share loss key tumor type melanoma rcc nsclc
adjuv use add potenti upsid continu grow strong posit
adjuv melanoma base
howev opdivo sale less certain short term given keytruda domin
nsclc base robust surviv data chemo combin
monotherapi adopt keytruda standard care
first line erod opdivo nsclc share place spotlight full checkmate-
part nsclc data present esmo see discuss
april approv mrk keytruda inlyta combin front-lin rcc base
strong data may also threaten opdivo share import
indic garner first-mov advantag compani
approv rcc includ opdivo mono approv novemb
opdivo yervoy approv april mrk phase result
surpris first achiev os co-primari endpoint
rcc first interim look kol conclud prompt
overwhelm shift toward keytruda inlyta across line therapi howev
august seen reduct opdivo use rcc suggest
regimen primarili replac singl agent tki use long-term
data emerg opdivo yervoy profil may strengthen longer
surviv rcc current largest tumor type io estim revenu
current estim rcc compris opdivo total
compani data includ prior accumul revenu franc germani book
estim opdivo captur rcc market
opdivo yervoy nsclc market opdivo monotherapi
metastat melanoma market opdivo yervoy opdivo mono
adjuv melanoma market opdivo mono howev mention
competit pressur like decreas market share rcc
nsclc near-term
bristol jointli own patent cover opdivo patent
expir decemb includ extens
eu includ extens patent cover opdivo japan expir includ
extens assum ono receiv mid-singl digit royalti sale mid-
to-high singl digit royalti outsid
estim opdivo sale indic
march opdivo approv dose everi week
addit fixed-dos option opdivo also receiv approv
shorter infus time vs prior hour updat dose appli
approv indic dose aim provid conveni dose
option monotherapi indic also may use opdivo therapi post
initi combo dose eu approv dose regimen melanoma
rcc well fix minut dose option six
approv monotherapi indic receiv april physician expert
approach week formul caution approv base
bioequival data oppos clinic studi addit keytruda approv
eu file dose
januari bristol/ono merck announc global licens agreement
settl patent infring litig relat use cancer treatment
agreement dismiss prejudic patent litig pertain keytruda part
agreement merck made initi payment record
bristol/ono record merck also pay royalti global keytruda
indication-tri namephasen primari endpointprimari completionnsclc nivo chemo nivo egfr chemo relatlimab adjuv resect stage /- lymphomanivo brentuximab vedotin neck cancer nivo cancernivo adjuv resect stage oxaliplatin fluoropyrimidin cancernivo chemo myelomanivo pomalyst /-emplic disease-fre surviv dor durat respons orr object respons rate os overal surviv progression-fre surviv rf recurrance-fre surviv
sale
royalti split bristol ono compani
also grant certain right respect patent portfolio
pertain bristol also taken legal action compani
market agent seek financi remedi
base promis data bristol initi phase checkmate-
august trial assess differ combin opdivo nsclc
stratifi differ express level vs platinum-bas chemo part
opdivo /-yervoy part opdivo yervoy part
opdivo chemotherapi all-com top-line os nsclc stratifi
express opdivo yervoy opdivo chemo releas juli
summar result provid addit perspect glean
speak manag well expect gather survey cowen
health confer march full data part present esmo
part opdivo yervoy met co-primari endpoint os patient
bristol provid addit specif howev file plan opdivo
monotherapi arm mention releas file plan data
like underwhelm conjectur data show clear contribut
compon opdivo yervoy individu add os benefit opdivo alon
suffici achiev signific bristol suggest tail curv
complet respons rate could distinguish major investor clinician poll
cowen health confer march anticip os hr
opdivo yervoy investor expect patient aliv end trial
clinician expect comparison patient aliv
keytruda month mo month patient would
expect aliv month chemotherapi
cowen compani
part opdivo yervoy demonstr surviv benefit exploratori analysi
patient signific appar achiev alpha
power appli previously-pres tmb analysi see
present expect see compel trend part trial also includ
opdivo chemotherapi arm mention releas assum
impli compel trend achiev opdivo chemotherapi arm
patient
part opdivo chemotherapi meet primari endpoint os
nonsquam nsclc regardless express os hr vs chemotherapi
alon non-squam patient ci signific
howev bristol note chemo-alon arm perform much better
competit trial therefor provid high bar opdivo chemo cross mo
landmark os opdivo chemotherapi vs chemotherapi alon
vs vs competit trial mo
squamou nsclc impress vs hr ci
squamou histolog primari endpoint trial despit
observ fda must follow law requir guid outcom
clinic trial fda may depart presenc substanti evid
caution differ control arm perform often explain
differ enrol popul diseas burden perform statu prior
therapi etc unlik sway opinion across opdivo chemo arm
part trial major investor clinician poll cowen health
confer march anticip hr
opdivo yervoy differenti vs keytruda chemo could higher cr rate
and/or greater landmark os patient howev clear
differenti evid present septemb may
requir longer follow-up result believ opdivo yervoy garner
signific share nsclc near/intermedi term bristol combin
like role patient clear us size characterist
segment part file patient file pursu base
tmb manag note oncologist practic commun hospit mani
physician treat rcc melanoma thu familiar
opdivo yervoy combo low-dos yervoy also improv safeti profil
increas comfort level regimen offer chemo-fre regimen
front-lin low patient anoth potenti advantag
part opdivo chemo vs chemo achiev endpoint
appear salvag outlier perform chemo arm os month
vs real-world estim month vs month
fulli explain crossov immunotherapi patient receiv io
second-lin similar lower compar trial bristol see trend
indic systemat problem clinic trial design recruit
suggest swing surviv rate may extent stochast compani
made signific invest last year collect real world
evid rwe could help reveal relev averag valu surviv
rwe use payor negoti possibl regulatori file
futur whether play role nsclc regulatori review fda
agenc view extern data rwe yet clear
februari bristol announc combin nivolumab ipilimumab
met co-primari endpoint chemotherapi patient high-tmb
mutations/megabas regardless express statu approxim
tmb-evalu patient determin high tmb bristol present interim
result april high-tmb patient median month
nivolumab ipilimumab combin vs month chemotherapi
combin therapi demonstr numer improv
tmb-evalu popul differ statist signific
broader group within high-tmb popul benefit seen
across squamous/non-squam histolog express level os
still immatur time analysi present high-tmb patient
even though os endpoint ultim assess statu median os
month combin therapi month chemotherapi
separ trend toward io combo formal test
cowen compani
base part data file eu nsclc
patient tmb mut/mb across squamou non-squam tumor histolog
across express spectrum eu file origin accept may
 file origin accept june octob
howev announc fda chmp request addit
inform includ os data low tmb patient part octob
press releas describ fda eu extens provid select data
updat low tmb patient mut/mb median os month
opdivo yervoy vs month chemo high tmb patient
mut/mb median os month opdivo yervoy vs month chemo
delay month submiss low-tmb data fda pdufa date
set may januari howev bristol announc
withdraw applic opdivo yervoy nsclc base tmb
eu bristol request receiv clock-stop applic review upon
submiss addit data bristol await supplement chmp opinion
new data state juli pursuit tmb biomark
phase data nivolumab plu ipilimumab first-lin nsclc
present first time subsequ updat
initi data
nivolumab plu ipilimumab full dose present abstract mid-may
respons rate report time led investor concern given
nivolumab monotherapi deliv respons full data present
show even modest respons rate patient
patient one-year os par
histor mo month mpf month platinum-bas
underwhelm data driven high toxic grade high
discontinu rate drug-rel death given high toxic
full nivo ipi dose bristol began enrol addit cohort ipilimumab
dose frequenc lower nivo plu low dose ipilimumab data first
present show substanti better efficaci toler
full nivo ipi dose show orr grade drug relat death
opdivo low-dos show orr grade drug
dose pivot phase panelist conclud
combo regimen effect opdivo alon similar toler
data updat
updat show yervoy addit effect
opdivo orr os respons rate monotherapi vs combo vs
patient vs express vs
express median monotherapi vs combo vs month
patient vs month express vs nr
express one-year os monotherapi vs combo vs
patient vs express vs express
intriguingli addit yervoy opdivo increas respons rate also
egfr patient popul usual consid unrespons
monotherapi addit led increas rate grade toxic
combo vs nivo alon importantli treatment relat
death report studi treatment relat lead discontinu
combo vs nivo alon
os data present combo opdivo yervoy
surviv vs patient vs patient express
vs patient express
declin os year vs year expect consist across arm
durat os continu differenti chemo alon given os
chemo typic howev differ os opdivo yervoy
opdivo monotherapi mix combin perform better patient
express opdivo alon perform better
patient express patient number small difficult
draw firm conclus abstract also report first time os data
patient underwhelm par histor
wclc updat provid combin opdivo chemo
platinum doublet arm patient treat minimum follow-up
month orr mdor month ci mpf
month ci mo month ci os
rate patient patient express mo
month os rate patient express
mo month os rate also
bristol select dose linger question investor
mind howev smoker appear perform better vs dose
rational puls frequent consist pressur tumor
june bristol publish jco data combin nivolumab
platinum-bas doublet first line nsclc fifty-six patient
random nivolumab mg/kg plu gemcitabine/cisplatin cohort
plu paclitaxel/carboplatin cohort nivolumab mg/kg plu paclitaxel/
carboplatin cohort grade trae report patient
patient pneumon twenty-on percent patient discontinu therapi
result tr common grade includ fatigu nausea
decreas appetit alopecia anemia rash diarrhea
overal frequenc grade trae par histor platinum-
base chemotherapi alon howev frequenc immune-medi
skin gi renal pulmonari organ greater expect single-ag
nivolumab effect manag corticosteroid infliximab
object respons rate cohort cohort
cohort cohort four-week
respect mpf month two-year os rate
respect
skeptic chemo combo believ impress respons rate
translat longer os one-year surviv combin chemotherapi
par opdivo monotherapi higher toxic burden
jco paper conclud unclear whether nivolumab plu platinum-bas
chemotherapi offer os benefit vs nivolumab monotherapi howev also note
mpf shown month appear subpar compar month
shown believ may reflect intrins pharmacolog differ
molecul also note use alimta carboplatin chemo
backbon test use keytruda dose mg time
lower base differ resolv test lower opdivo dose
assess allow physician
choos cisplatin vs carboplatin alimta vs gemcitabin
first line studi compar opdivo
advanc metastat nsclc august announc
studi achiev primari endpoint express cut-off full
data present esmo octob show nivolumab reduc
risk progress death vs platinum-bas chemotherapi ci
patient advanc nsclc express mpf month
nivolumab month platinum-bas chemotherapi nivolumab also
reduc risk death ci patient express
hr favor chemotherapi express respons rate
chemotherapi opdivo opdivo better toler grade
opdivo vs chemo
examin opdivo yervoy mainten follow prime cycl chemo
trial project enrol newli diagnos advanc nsclc patient
random triplet regimen chemotherapy-onli trial design
primarili offer chemo-spar option addit safeti benefit spare
chemo up-front may give clinician treatment option later line
enrol all-com recruit steadi bristol see neg
patient attract opportun given regimen
penetr popul lesser extent penetr vs
expect read
bristol current foothold nsclc second-lin set increasingli
repres patient receiv immunotherapi primarili keytruda /- chemo
front-lin longer good candid opdivo bristol roll bla file
nivolumab complet end base phase ii studi line
squamou nsclc data present show
median os month orr estim one-year surviv
data updat show one-year os os
data consist earlier phase result
show surviv rate favor compar histor os
current soc
opdivo receiv approv earli march use metastat squamou
nsclc progress platinum-bas chemotherapi approv
base also stop
overwhelm efficaci two month approv octob label
expand non-squam histolog base
also stop earli overwhelm os benefit
june bristol announc china nation drug administr cnda
approv opdivo monotherapi nsclc approv base phase
trial enrol patient chines make opdivo first
inhibitor approv china expans china increas top-lin
growth strategi timelin disclos
class advanc front-lin treatment avail
elig patient shrunk insight gain clinician treat
patient fail monotherapi chemo-combo standard
yet set modest percentag monotherapi failur would like elig
switch anoth clinic trial chemotherapi
taxan appear current mainstay
earli januari bristol announc checkmat trial squamou
nsclc stop earli efficaci note nsclc account lung cancer
squamou histolog less preval nsclc full data
present updat nivolumab reduc risk
death compar current soc docetaxel help patient live month
longer median os month nivolumab compar month
docetaxel orr nivolumab compar docetaxel importantli
statist os benefit express independ respons durabl
median dor month nivolumab compar docetaxel
nivolumab also substanti better toler docetaxel grade
compar docetaxel updat os present
os opdivo vs docetaxel os
opdivo vs docetaxel
present os data opdivo patient aliv vs
docetaxel patient aliv hr
april bristol announc non-squam nsclc
stop earli overwhelm efficaci note nsclc account lung
cancer non-squam histolog preval nsclc
full data present show nivolumab reduc risk death
vs soc help patient live almost three month longer compar
docetaxel median overal surviv month nivolumab vs month
docetaxel orr nivolumab vs docetaxel os benefit
correl express nivolumab statist superior docetaxel
patient express respons durabl
median durat respons month nivolumab vs month
docetaxel nivolumab also substanti better toler grade
compar docetaxel overal surviv updat show
year os opdivo vs docetaxel os opdivo
vs docetaxel
esmo os data present show opdivo patient
aliv versu docetaxel patient
opdivo approv melanoma singl agent combin yervoy
 irrespect braf statu approv base
monotherapi
combin bristol estim opdivo
monotherapi captur market share metastat melanoma
opdivo yervoy captur decemb approv
fda use adjuv melanoma set base trial
evalu opdivo vs yervoy patient stage iiib/c stage iv melanoma
eu approv adjuv use grant juli bristol abl
capit adjuv melanoma set first-mov advantag merck
sbla keytruda monotherapi approv februari bristol estim
opdivo monotherapi captur adjuv melanoma market
expert previous believ keytruda agent choic given
conveni dose vs opdivo howev avail
opdivo yervoy combin revers trend demonstr superior rf
orr long-term os opdivo yervoy current standard
care patient patient opdivo keytruda monotherapi
equal foot keytruda maintain small edg given conveni
dose braf patient io use ahead braf/meki nvs/rhhbi given
promis long-term benefit braf/meki use post io patient
rapidli progress diseas rapid respons need braf/meki usual act
rapidli deliv transient respons io
bristol present latest updat phase data opdivo
monotherapi treatment experienc melanoma major
patient previous treat therapi includ braf
inhibitor immunotherapi data show os
evid plateau surviv approxim four year
impress given seer cite os patient treat
advent io
interestingli protocol allow re-treat opdivo patient origin
achiev respons subsequ progress among five patient re-
challeng opdivo achiev complet respons stabl diseas
first evid patient re-challeng opdivo achiev clinic benefit
confirm would expand commerci opportun opdivo may use
one time treatment paradigm
advanc melanoma random patient either opdivo investig choic
chemotherapi icc respons rate opdivo vs
icc grade drug relat opdivo vs icc common drug
relat increas lipas increas alt anemia fatigu opdivo vs
neutropenia thrombocytopenia anemia icc
phase compar opdivo vs dacarbazin dtic
treatment-nav advanc melanoma studi met os primari endpoint one-
year surviv opdivo vs dtic hr respons rate
opdivo vs dtic opdivo shown superior
dacarbazin irrespect express patient os
opdivo dacarbazin os opdivo
dacarbazin
fewer discontinu observ opdivo dtic vs well
treatment-rel grade vs common opdivo
treatment-rel fatigu pruritu nausea
death attribut studi drug toxic either arm
result ipilimumab combin nivolumab
receptor antagonist present publish nejm studi
phase ib dose-rang studi enrol advanc melanoma patient treat
either concurr sequenti dose popul enrol highli
refractori receiv prior system therapi respons
rate patient treat concurr dose schedul vs
patient treat sequenti dose respons deep
post-hoc analysi show patient concurr dose arm tumor
reduct vs patient sequenti dose updat os data
show one-year os os across patient
enrol confirm cr rate increas respons across
braf mutat statu express level grade treatment-rel
occur patient concurrent-regimen sequenti
regimen respect treatment-rel death
bristol initi phase ii studi evalu
combin nivo ipi vs ipi monotherapi treatment advanc melanoma
studi evalu orr primari endpoint secondari endpoint
earli interim result present concurr publish
nejm april braf wild-typ patient combin treatment
demonstr orr cr vs orr yervoy alon cr
 median braf wild-typ patient reach
time assess braf mutant patient combin treatment also
significantli decreas risk progress median braf
mutant patient month combin regimen vs month yervoy
septemb fda grant acceler condit approv
opdivo yervoy treatment patient braf wild-typ
unresect metastat melanoma approv larg base phase ii
trial first pivot studi demonstr efficaci
combin approv conting upon verif addit
confirmatori trial phase show favor surviv
data combo
bristol present updat provid long-term
verif data result demonstr orr combo
cr vs ipilimumab alon cr median reduct tumor burden
combo compar increas alon one-year
opdivo ipi vs ipi opdivo ipi vs ipi one-
year os opdivo ipi vs ipi os opdivo ipi
vs ipi grade combo compar ipi alon
common skin gastrointestin endocrin hepat
phase trial advanc melanoma assess
combin opdivo yervoy vs yervoy monotherapi opdivo monotherapi
random first present data continu follow
patient long-term treatment
interim data show mpf month nivo ipi month
nivo alon month ipi alon combin demonstr
reduct risk progress vs ipi vs ipi alon
respons rate combin cr nivo alon cr
ipi alon
treatment-rel nivo ipi nivo ipi tr
lead discontinu nivo ipi nivo ipi diarrhea
experienc patient combo nivo ipi
importantli patient discontinu nivo ipi due trae achiev
respons discuss conclud nivo ipi pois becom
new standard care melanoma combin treatment demonstr
superior efficaci compar single-ag notabl superior opdivo yervoy
vs opdivo observ patient patient
april present os data subsequ publish
complet os analysi nejm septemb nejm public
mo month opdivo monotherapi month ipilimumab
monotherapi reach opdivo ipi combin statist
comparison combin treatment demonstr signific surviv benefit vs
ipilimumab monotherapi opdivo monotherapi also
opdivo yervoy combin treatment demonstr numer statist
surviv benefit vs opdivo monotherapi os rate
combo treatment opdivo alon ipi alon os rate
combo treatment opdivo mono ipi mono
subgroup analysi os suggest certain subgroup includ brafmut
low express may favor opdivo yervoy combo vs opdivo
monotherapi melanoma especi brafmut patient howev
therapeut benefit less clear high express
octob present surviv data summar
chart briefli opdivo arm either opdivo-alon opdivo yervoy continu
demonstr durabl respons sustain surviv benefit median
month yervoy month opdivo-alon month
opdivo yervoy combin hr opdivo vs yervoy hr
opdivo yervoy vs yervoy four-year os rate yervoy
opdivo opdivo yervoy data analysi subsequ
publish lancet oncolog
os rate opdivo yervoy combo still moder less
steep declin compar opdivo monotherapi unreach mo
combo highlight impress treatment durabl unreach median time
subsequ system therapi mtsst like power result show greater
depth treatment increas probabl remiss
cowen compani
decemb opdivo first io treatment approv
adjuv set evalu nivo vs adjuv immunotherapi
prevent diseas recurr resect stage iiib/c stage iv melanoma
despit project primari endpoint complet set novemb bristol
announc primari endpoint recurrence-fre surviv rf met
plan interim look data demonstr statist signific improv
rf opdivo compar yervoy sustain rf
benefit month vs respect data present esmo
publish new england journal medicin septemb
subsequ opdivo achiev earli fda approv end receiv eu
approv juli receiv approv japan august
updat provid opdivo continu demonstr
superior rf vs yervoy popul
analysi show opdivo demonstr superior rf regardless diseas
stage express braf mutat statu rf stage iiib
opdivo vs yervoy rf stage iiic opdivo vs
yervoy bode well use opdivo adjuv set bristol
current pursu aggress phase clinic trial across tumor type
melanoma lung renal bladder gastric head neck liver use
io therapi adjuv set potenti becom larg treatment
opportun especi tumor tradit early-detect melanoma
bladder renal breast gastric colorect cancer
vs ipinivo ipi vs os deathnivo vs ipinivo ipi vs reach tsst time subsequ system therapi
rf benefit opdivo across subgroup
juli receiv approv nivolumab japan
treatment unresect melanoma chemotherapeut agent dacarbazin
approv agent melanoma japan approv dose given everi
week less util primari dose on-going bmy-
sponsor trial read noth differ dose approv base
small phase ii studi run ono post market studi requir due limit
number japanes patient receiv drug clinic trial opdivo
launch septemb japan full reimburs bristol receiv royalti
nivo sale japan estim single-digit rang japan
frontlin monotherapi approv februari opdivo yervoy combin
therapi approv may adjuv monotherapi approv
bristol present updat surviv data phase ii
studi second/third line renal cell carcinoma studi enrol
patient fail least prior line show median os
month patient treat mg/kg mg/kg mg/kg nivolumab
bristol select mg/kg dose pursu phase
base design compar efficaci
opdivo afinitor mtor inhibitor nv second line mrcc studi stop
earli juli os benefit mark third paradigm shift trial
stop earli approv grant fda novemb eu
april
ecc septemb bristol present full result checkmat opdivo
demonstr median os benefit month compar month
everolimu reduct risk death clinic benefit opdivo
observ irrespect express patient mo month
vs month everolimu patient mo month mo
compar everolimu orr nivolumab compar
everolimu nivolumab also show better toler everolimu grade
compar everolimu updat data present novemb
show os rate opdivo vs everolimu
nivolumab show unequivoc superior everolimu os benefit line
expect nivolumab everolimu perform slightli better
anticip expect mo month nivolumab
month everolimu data show month nivolumab everolimu
like reflect less refractori popul anticip express
independ efficaci expect phase ii trial patient
experienc much longer os reason differ outcom
compar phase ii multipl may includ differ dose regimen
differ threshold use express posit
august bristol announc opdivo yervoy vs sutent
rcc achiev orr endpoint co-primari endpoint io/io combin
vs sutent howev trial fail achiev statist
benefit co-primari endpoint month vs month part
high statist hurdl power-alloc design os endpoint
septemb bristol announc stop earli
meet os co-primari endpoint assess intermediate/poor-risk
popul plan interim analysi earli data present esmo
septemb novemb esmo septemb bristol
present os data intermediate-/poor-risk popul primari endpoint
assess intent-to-treat popul assess secondari endpoint
co-primari endpoint os intermedi poor-risk patient popul
opdivo yervoy reduc risk death compar
sutent time analysi mo reach popul
opdivo yervoy month sutent evalu secondari endpoint
opdivo yervoy also demonstr os benefit random patient reduc
risk death mo reach
patient treat opdivo yervoy vs month patient treat
sutent novemb combin also demonstr os benefit
across statu ci neg patient
ci posit patient although
treatment-rel death opdivo yervoy vs sutent earli data
impress base earli separ os-curv combo superior
cowen compani
april data report nejm public combin
opdivo yervoy approv rcc opdivo yervoy quickli becam
soc frontlin set enjoy lion share rcc
compani approv tumor type combo
opdivo monotherapi howev juli chmp adopt neg opinion
appar due inadequ demonstr contribut compon bristol
appeal chmp gave posit opinion novemb combin
approv eu januari
august long-term follow-up data publish lancet oncolog
median follow-up month intermediate/poor-risk rcc patient regardless
statu treat opdivo yervoy continu exhibit superior os rel
sutent median reach ci estim vs month
hr ci overal surviv ci
versu intriguingli although benefit initi seen
curv separ month median durat respons
popul still reach see intermediate/poor risk patient
higher opdivo yervoy vs
patient complet respons maintain respons long-term follow-up
data preliminarili present one kol deem
impress result confer certain extent data
support bristol content opdivo yervoy io/io combin broadli
may shine long-term follow-up exhibit deeper durabl respons
compar io/chemo io/tki combin long term follow-up
keytruda inlyta need draw definit conclus
cowen compani lancet oncolog os intermediate/poor risk
dor
octob announc combin keytruda inlyta phase
hit os co-primari endpoint treatment all-com
advanced/metastat rcc februari present
data median follow-up month combin
treatment achiev os co-primari endpoint assess
popul median month keytruda inlyta vs month
sutent median os reach either treatment group
howev surviv achiev combo-tr patient vs
sutent-tr patient result keytruda inlyta
combin consist across imdc risk categori express group
compar data opdivo yervoy vs mrk keytruda
inlyta mrk combo outperform popul os see chart
result kol conclud prompt overwhelm shift toward
keytruda inlyta across line therapi patient toler
combin high-risk patient immunosuppress drug
autoimmun condit like still receiv single-ag vegf inhibitor vs
checkpoint inhibitor combo otherwis believ era tki monotherapi
rcc keytruda inlyta soon becom standard care
one kol adam join shift toward keytruda inlyta
pend evid durabl complet respons whether respons
maintain off-treat view keytruda inlyta combin io therapi
parking-break cite data suggest less-than-addit effect
two agent less immune-rel toxic keytruda inlyta vs keytruda
single-ag therapi suggest keytruda isnt exhibit full immun effect
appear like group vs group suggest
vegf inhibitor drive activ keytruda inlyta stop
patient progress case singl agent
patient stop keytruda monotherapi continu respond kol look
long-term follow-up data month would feel comfort
switch keytruda inlyta
nivolumab deliv respons rate heavili pretreat classic
hodgkin lymphoma patient previous fail autolog stem cell
transplant adcetri phase complet partial
respons respect median reach
week follow-up overal surviv year overal surviv year
data first present publish nejm
editori note hodgkin lymphoma appear highli sensit blockad
opdivo may move earlier treatment paradigm allow patient spare
short- long-term toxic chemotherapi
data confirm larger phase ii studi
show respons rate complet respons rate
partial respons rate respons durabl median durat
respons month mpf month os base
fda approv nivolumab chl may
ema approv novemb label combin data studi
cite median durat respons
month longer term follow-up data month report june
overal orr rang estim sale opdivo chl
dec data phase i/ii studi opdivo combin
antibodi drug conjug adcetri show respons rate pre-
transplant relaps refractori classic hodgkin lymphoma complet metabol
respons experienc patient infus relat reaction
experienc patient protocol amend institut requir
premed low-dos corticosteroid opdivo current approv chl
patient relaps progress hematopoiet stem cell transplant
adcetri data present suggest opdivo may move earlier
treatment paradigm combin adcetri bristol note combo
also explor frontlin older chl nhl patient discuss data
enthusiast regard efficaci argu hodgkin lymphoma could
first cancer cure io least small subset patient
follow-up data phase i/ii opdivo adcetri studi present ishl
octob decemb median follow-up month
evalu patient orr cr pr neither mpf mo
reach howev os rate rate
patient treat opdivo adcetri rate
elev patient underw asct treatment patient
cr lower patient saw pr achiev stabl
diseas decemb data patient part concurr
dose also present median follow-up month patient
evalu orr cr pr sd pd among
part patient went directli asct complet opdivo adcetri
median cells/kg collect median time neutrophil engraft
day median time platelet engraft day
patient requir addit salvag therapi rate all-treat pt
cr rate opdivo adcetri combin therapi r/r chl nearli doubl rate
report either agent individu suggest possibl complementari
mechan opdivo adcetri pathway strong phase ii
result bode well pivot phase evalu opdivo adcetri
vs adcetri alon r/r chl patient inelig asct trial initi may
estim primari complet novemb assess primari
opdivo approv cancer account sale
on-going phase pc august move opdivo
first line without yervoy combin prospect trial dampen
howev recent announc analog phase ii
studi fail meet primari endpoint orr dor meanwhil keytruda /-
chemotherapi earn approv june base
threaten erod opdivo share
opdivo origin approv platinum refractori cancer
novemb eu april label cite os benefit key
strateg advantag prevent azn file hawk base
respons rate keytruda origin grant acceler approv
august base respons rate data confirm novemb
os benefit popul month vs month soc
bristol announc late januari dmc stop phase checkmate-
earli overwhelm efficaci platinum-refractori head neck cancer
full data show interim valu critic valu
declar superior opdivo reduc risk death compar
investig choic standard care mo month vs month
investig choic standard care includ methotrex docetaxel cetuximab
importantli efficaci sustain
patient efficaci sustain hpv hpv- patient
opdivo substanti better toler soc grade opdivo
vs soc opdivo improv vs soc vs month
associ modest improv respons rate vs
april updat present patient treat
opdivo mo month ci vs chemotherapi mo
month ci reduct risk death ci
surviv rate opdivo ci vs
ci chemotherapi treatment opdivo continu demonstr
os benefit analyz subgroup hpv
hpv- statist signific differ
opdivo chemo ci
februari opdivo receiv acceler approv bladder
cancer base tecentriq roch approv may keytruda
merck imfinzi astrazeneca bavencio approv may
opdivo receiv eu approv bladder june becom first eu
approv io agent indic howev opdivo time advantag eu
approv short-liv tecentriq keytruda receiv posit chmp
opinion bladder cancer juli subsequ approv
septemb
current pursu pivot phase bladder cancer trial phase
initi februari evalu opdivo monotherapi
vs placebo studi assess disease-fre surviv primari outcom
estim primari complet april also pursu phase
bladder cancer includ experiment arm test
opdivo yervoy opdivo chemo vs soc chemo evalu os
co-primari endpoint estim primari complet juli
approv bladder cancer grant base phase ii
evalu opdivo monotherapi bladder cancer data publish lancet
januari intent-to-treat independ popul show
respons rate cr pr median os month mpf month
respons rate patient patient
patient
phase i/ii evalu opdivo monotherapi opdivo yervoy
combin therapi metastat solid tumor includ patient bladder cancer
data nivolumab ipilimumab present show
superior efficaci compar respons rate
vs mpf vs month mo vs month grade tox
reason trae lead discontinu nivo ipi
respons rate best seen far io bladder appear
superior tecentriq mono label nivo mono cm-
durvalumab mono mo also compel given
tecentriq shown month less refractori popul prior
line vs sixth tumor ipi show addit effect
nivo nsclc melanoma rcc gastric sclc bladder also noteworthi
higher ipi dose prove superior lower ipi dose increas toxic
 reach tsst time subsequ system therapi
octob present updat data result opdivo
monotherapi appear slightli better found phase ii
demonstr orr median month median os
month opdivo yervoy orr mpf month mo
month opdivo yervoy orr mpf month
mo month treatment result show highli durabl respons
rate surviv benefit compar previou result present
march bristol initi phase ii trial treatment
patient dna mismatch repair/microsatellit instabl high metastat
monotherapi cohort well follow opdivo combin opdivo yervoy
cohort opdivo yervoy cobimetinib cohort opdivo anti-
cohort opdivo daratumumab cohort
januari gi bristol first present data opdivo monotherapi
arm report orr patient prior foi treatment
enrol patient januari assess durat respons os
median yet reach april fda grant prioriti review
opdivo monotherapi dmmr/msi-h follow public opdivo
monotherapi result lancet oncolog juli patient assess
median follow-up month patient achiev investigator-assess
orr patient diseas control week longer median dor
reach respond aliv patient respons
last month longer late-juli fda grant acceler condit
approv opdivo monotherapi adult pediatr year older patient
dmmr/msi-h post treatment fluoropyrimidin oxaliplatin
irinotecan foi approv grant base orr dor achiev thu far cm-
june first data combin opdivo yervoy present
patient combin orr averag length
respons month thu far respons still on-going dcr
report os rate addit data
present gi januari simultan publish journal
clinic oncolog evalu patient median follow-up month
investigator-assess orr ci diseas control rate
week median dor reach still on-going cut-off
rate opdivo yervoy group month year os
rate opdivo yervoy group month year grade
treatment-rel occur patient drug-rel discontinu
rate new safeti signal treatment-rel death report
conclus treatment opdivo yervoy msi-h demonstr high
respons rate well encourag os rate show
manag safeti respons surviv outcom combin appear better
monotherapi albeit off-set slightli higher treatment-rel juli
fda approv opdivo yervoy adult dmmr/msi-h post
treatment fluoropyrimidin oxaliplatin irinotecan foi
octob present updat demonstr
durabl benefit opdivo yervoy combin patient
median follow-up month orr cr dcr week longer
follow median os rate median
rate neither median os median reach cutoff
septemb opdivo receiv approv treatment hepatocellular
carcinoma non-respond sorafenib approv base phase ii
show rel low respons rate median dor
month singl arm trial also examin opdivo yervoy
updat provid show month os
rate high patient treat opdivo mg/kg yervoy mg/kg
dose orr group twice opdivo monotherapi
howev file combin phase trial
report june phase examin
opdivo monotherapi vs sorafenib also intend confirmatori fail
achiev primari os endpoint ci file
longer tabl posit surviv trend may enough maintain
opdivo use alreadi withdrawn eu file opdivo line
also pursu phase evalu opdivo vs
placebo adjuv set patient high-risk recurr
initi decemb estim primari complet date april
earli opdivo data provid insight efficaci rel agent
small phase i/ii studi advanc highli pretreat hepatocellular cancer
patient present nivolumab show orr sustain across
viral infect viral uninfect patient overal surviv
time point durabl respons observ
across dose level etiolog cohort encourag first look nivo
liver cancer especi consid studi enrol highli refractori popul
fail current standard therapi sorafenib os shown studi
appear superior azn tremelimumab vs despit tremelimumab
superior orr suggest possibl less durabl respons
compar repres anoth difficult-to-treat cancer respond
opdivo acceler approv sclc trial failur quell first-mov
august opdivo becam first io treatment approv sclc
set appear well-posit two addit phase trial near
complet howev octob announc opdivo yervoy miss
os primari endpoint sclc novemb bristol
announc opdivo yervoy es-sclc meet
primari os endpoint bristol sclc market share diminish roch chemo
combo gain approv earli shown rapid uptak
addit earn sclc approv keytruda base keynote-
estim ww sclc io market size
domin near term roch
octob bristol announc opdivo monotherapi phase checkmate-
achiev primari os endpoint vs soc chemotherapi sclc data
present esmo-io decemb mo month chemo
vs month opdivo orr rate similar chemo
opdivo opdivo greater dor month vs month chemo lack
surviv benefit clear disappoint
novemb also announc opdivo yervoy combo arm phase
achiev os primari endpoint treatment
extens stage small cell lung cancer es-sclc
platinum chemo august opdivo gain acceler condit
approv base monotherapi result phase i/ii
combin opdivo yervoy also assess high
discontinu prevent earli approv phase confirmatori trial
phase i/ii opdivo yervoy demonstr promis efficaci phase i/ii
orr mdor month mo month combo fail achiev
statist signific larger random trial assess challeng os
endpoint though statist alloc disclos
comment monotherapi arm descript secondari endpoint
failur signific miss without opdivo chemo
combin studi part develop strategi appear near-
term opportun advanc opdivo therapi mainten sinc
monotherapi arm descript secondari endpoint opdivo unlik
opdivo receiv acceler condit approv sclc august base
sclc cohort phase i/ii assess arm
nivolumab monotherapi nivolumab ipilumumab combin present
sclc patient treat nivolumab
sclc patient treat nivo ipi orr patient treat
nivolumab monotherapi vs patient treat nivo ipi median os
month monotherapi month combin importantli
combin appear deliv long-term surviv advantag os
vs importantli respons observ platinum-sensit platinum-
resist patient respons rate monotherapi vs combo vs
patient vs neg patient vs posit
patient grade observ nivolumab-tr patient compar
patient treat combin three treatment-rel death
report overal combin nivolumab ipilimumab deliv superior
efficaci versu nivolumab alon also associ higher toxic burden
octob world lung bristol present updat data sub-
group patient evalu tmb tumor mutat burden high tmb group
orr opdivo opdivo yervoy os opdivo
opdivo yervoy data suggest tmb possibl predict biomark
combo
esophag januari announc opdivo monotherapi achiev
primari endpoint os vs chemo phase trial unresect
esophag cancer studi result present although much
smaller tumor type new case per year esophag cancer appear
anoth battleground compani purs indic
like first-mov advantag addit on-going phase trial
opdivo monotherapi adjuv set estim primari
complet septemb opdivo yervoy estim
primari complet may
gastric small phase studi present patient
chemotherapy-refractori gastric cancer treat either nivolumab
combin nivolumab ipilimumab respons rate monotherapi
combin complet respons report group mo
month nivolumab month combin phase studi
combin nivolumab ipilimumab treatment gastric gej cancer
on-going primari complet march
novemb bristol announc phase studi japan
opdivo monotherapi advanced/recurr gastric cancer met primari endpoint
os data report month ahead primari complet date
decemb fda grant opdivo orphan drug design gastric cancer
gastric-esophag junction cancer septemb opdivo receiv approv
japan gastric cancer post chemo failur per compani preval
gastric cancer highest asian countri second common cancer
glioblastoma bristol report posit earli data use nivo ipi
recurr glioblastoma nivolumab deliv mo month nivo
ipi mo month os nivolumab alon
nivo ipi base find phase cohort ad compar nivo
monotherapi bevacizumab howev april bristol report nivo
meet primari endpoint os cohort may announc
phase opdivo radiotherapi vs temozolomid radiotherapi meet
primari endpoint still phase on-going
opdivo radiotherapi temozolomid pc februari august compani
report trial fail meet co-primari endpoint os
would continu track success still possibl outlook poor given
aggress gbm
liquid tumor bristol present data nivo ipi variou liquid tumor
nivo ipi deliv chl b-cell nhl t-cell nhl
safeti profil line prior studi view data underwhelm
opdivo monotherapi deliv chl b-cell nhl t-
cell nhl yervoy seem offer addit effect opdivo liquid tumor
stark contrast solid tumor synergi shown nsclc sclc
melanoma rcc bladder present suggest combo
develop liquid tumor may focu nk cell engag lirilumab
septemb fda place partial clinic hold phase
phase phase ii three trial evalu opdivo combin
pomalidomid lanalidomid multipl myeloma mm due risk seen keytruda
trial mm patient enrol opdivo trial allow continu
see clinic benefit new patient enrol decemb partial
hold lift trial hold lift
cervic cancer data present cohort phase i/ii cm-
trial opdivo advanc hpv cervic vagin vulvar cancer
orr primari endpoint cervic patient mpf month
mo reach respons seen cervic patient mean
durat respons reach month follow-up safeti profil
consist opdivo monotherapi
use io therapi adjuv set potenti becom
larg treatment opportun especi cancer tradit early-detect
 melanoma bladder renal breast gastric colorect howev
immunotherapi develop neo adjuv set straightforward
yet unvalid surrog endpoint major patholog respons mpr
defin viabl cell resect biopsi creat uncertainti whether
improv surviv predict without long-term follow-up also
concern delay surgeri accommod cours immunotherapi could
compromis outcom said compani approv io
therapi azn rhhbi strateg vy posit
adjuv space appear pois overcom develop hurdl phase
clinic trial read tumor type lung renal breast bladder
melanoma gastric colorect ovarian head neck liver merkel cell bristol well
posit phase clinic trial rhhbi across tumor type
adjuv set bristol lead melanoma gastric liver head neck
esophag
decemb opdivo becam first io treatment approv
adjuv set approv base stage iiib/c
stage iv melanoma opdivo demonstr statist signific
improv recurrence-fre surviv compar yervoy
recent updat neoadjuv opdivo imcis nsclc neostar
provid also show promis suggest immunotherapi use
feasibl set possibl even delay need surgeri combin
neoadjuv chemotherapi like import efficaci
bristol present initi efficaci data melanoma combo opdivo
patient receiv relatlimab mg plu opdivo mg iv orr
patient express nearli improv orr vs patient
less express treatment-rel grade occur
patient patient experienc grade
first io target efficaci data pdx ido given
data novel target underwhelm patient trial
heavily-pretr orr reason howev orr
abstract report orr patient enrol bristol
move pivot studi varieti tumor unspecifi
lead biomark express cell might consist
studi opdivo versu current regimen on-going
file time identifi given depend outcom studi
bristol also initi phase ii fraction-gc trial advanc gastric cancer
novemb describ fast real-tim assess io therapi
tumor type combin opdivo relatlimab assess one cohort
opdivo ipi opdivo ido inhibitor trial evalu
orr dor primari endpoint estim primari complet
novemb neither trial design result disclos thu far
februari bristol announc global collabor develop commerci
nektar lead asset pegyl version bias toward
phase i/ii data encourag appear lead
pathway asset develop partnership grant bristol exclus
cell carcinoma urotheli breast colorect gastric sarcoma combin
opdivo opdivo yervoy bristol exclus
right indic specifi time period collabor may also
evalu combin anti-canc agent either compani third
parti phase pivot trial evalu nivolumab melanoma
initi septemb studi evalu combin vs
nivolumab monotherapi co-primari endpoint orr os estim
primari complet august combin grant breakthrough
design fda august strength phase i/ii data
describ pivot phase trial studi opdivo rcc
initi decemb primari complet decemb
co-primari endpoint orr os phase ii trial studi nktr-
opdivo combin bladder cancer initi decemb
primari complet june orr
bristol made up-front cash payment equiti invest
nektar nektar also elig receiv addit mileston payment
development/regulatori mileston remaind sale
mileston nektar expect book global sale compani
split global profit nektar bristol share
develop cost bristol trial
nektar opdivo yervoy trial
compani agre specifi period time initi develop
overlap moa indic bristol estim collabor
dilut ep transact close
bristol initi enter collabor nektar septemb evalu
opdivo tumor type melanoma kidney colorect bladder nsclc
novemb initi safety/efficaci data phase i/ii trial
demonstr improv orr dcr albeit small patient number without
statist analysi especi neg rcc nsclc patient follow-up
januari demonstr similar orr dcr rate patient stage iv
march nektar provid updat report combin
opdivo show improv orr rcc
improv januari larg result two stabl diseas patient
convert respond march combin rcc show
orr patient statu
respond unknown patient
april failur studi combin keytruda
epacadostat anti-ido melanoma heighten risk regard develop
io combin kol investor center concern result obtain
small single-arm non-random studi interpret caution
skeptic extend trial also deriv single-arm studi
opdivo
present updat melanoma rcc nsclc result
well initi data uc tnbc cohort melanoma
patient analyz total orr fell target
respons need stage consid rel disappoint
patient continu treatment could potenti advanc
respons subsequ scan patient known statu
respond dose escal
reveal studi design propos pivot phase trial melanoma
opdivo combin compar opdivo monotherapi
nektar look enrol patient ecog similar stratif
stage statu studi evalu co-primari endpoint orr os
estim primari complet august
rcc report orr
data includ patient across dose escal dose expans
cohort stage target met respons
stage target also met respons updat
view encourag rcc note updat pembro
monotherapi rcc overal orr notabl lower orr
nsclc updat limit evalu cohort io-nav
patient one four dose escal phase origin report
well descript case studi nektar report
enrol patient howev scan updat neither stage
stage hurdl achiev patient remain
treatment given evolut soc
longer advanc develop pivot studi post-cpi
nsclc howev disclos patient enrol thu far
patient continu treatment patient one scan less
kol look least rr io set manag
disclos modifi pivot studi includ triplet-
combin nsclc melanoma rcc uc nektar
current evalu dose escal plan expand studi patient
present rr uc patient stage target met
respons stage target trial
continu enrol nektar declar plan advanc uc third indic
advanc pivot studi potenti registr path could
pursu io-nav cisplatin-inelig single-arm studi select
basi patient low statu baselin merck roch
report wors outcom patient make uc patient
tnbc report patient enrol still
treatment patient scan patient discontinu
therapi least patient one fewer scan indic cohort
fast-progressor unsurpris given challeng patient popul
nsclc expect phase trial focu consider opportun
second line set focus patient relaps refractori treatment
includ checkpoint inhibitor monotherapi well checkpoint inhibitor
combin chemotherapi regimen recogn paradigm defin result
show superior benefit combin pembrolizumab standard
care chemotherapi august inform withdrawn
accept abstract esmo data nsclc pivot trial
timelin initi phase trial uncertain
present updat data fulli enrol
melanoma cohort opdivo includ addit patient beyond
evalu patient orr
previous report cr pr on-going
orr patient cr patient cr
given month median follow-up current point benchmark
relev histor compar point
opdivo /- yervoy cohort month
median follow-up orr nivolumab monotherapi cr
ipilimumab nivolumab combin cr base updat
nivo combo appear well-posit rel nivo monotherapi
compar recent initi phase trial
gu februari present data evalu uc patient
data cutoff decemb cisplatin-inelig refus soc
known statu pend biopsi analysi remain
unscreen
orr steadi overal evalu popul includ
slightli increas cr indic increment respond overal
sinc abstract addit cr confirm
present importantli respond relaps continu treatment
three unconfirm pr confirm third came treatment
evalu patient orr statu
unknown remain efficaci evalu patient includ partial
respond evalu patient orr
encourag uc data continu show strong efficaci
compar treatment option cisplatin-inelig set
note popul commun set orr continu
superior observ gemcitabine/carboplatin orr
observ atezolizumab pembrolizumab patient make
popul
nktr present phase ii updat melanoma
notabl cr rate evalu patient median month
follow-up period march cut-off improv
report cr rate provid view
improv cr rate consist manag belief respons
potenti deepen time note approxim similar time
point term follow nivo ipi random cr rate
nivo monotherapi cr rate
confirm orr unchang orr report
among patient known pretreat statu orr
patient patient median follow-up
time month data immatur calcul median
septemb bristol acquir privat held ifm therapeut focus
develop therapi modul novel target innat immun
system lead compound includ preclin sting stimul interferon gene
agonist potenti enhanc innat immun
respons treat cancer bristol paid close may pay
mileston tie first two program subsidiari ifm therapeut ifm tre
dedic develop antagonist inflammatori condit acquir
novarti april
septemb bristol announc global collabor halozym develop
sub-cutan formul bristol io medicin use enhaz drug-deliveri
technolog base proprietari recombin human hyaluronidas enzym
enabl rapid drug deliveri bristol select sever io target includ pd-
option select addit target within five year maximum
target bristol pay halozym up-front may pay mileston
target plu addit payment combin product well
royalti sale product util enhaz believ royalti mid-
 juli bristol announc collabor evalu
rova-t opdivo opdivo yervoy treatment relaps extensive-
stage sclc trial initi data expect
septemb bristol announc collabor explor abbvi antibodi drug
conjug plu opdivo c-met overexpress nsclc phase studi
announc expect initi comment
combin could evalu solid tumor well
advaxi may bristol announc collabor advaxi evalu
adxs-dual immunotherapi target hpv-associ cancer opdivo
women metastat cervic cancer squamou non-squam fail
least one prior line chemotherapi advaxi sponsor studi
apexigen april bristol announc collabor apexigen evalu
combin opdivo activ solid tumor studi
initi june enrol patient metastat nsclc
fail chemo metastat melanoma fail prior io therapi
array may bristol announc collabor array biopharma
evalu binimetinib mek inhibitor opdivo opdivo yervoy patient
metastat microsatellit stabl array conduct phase studi
initi octob acquisit array june leav futur
collabor somewhat uncertain
calithera decemb bristol announc collabor calithera
bioscienc evalu oral glutaminas inhibitor phase i/ii studi
combin opdivo clear cell renal cell carcinoma ccrcc may
collabor expand evalu combo nsclc melanoma earli
interim result present melanoma nsclc rcc
rcc patient receiv checkpoint inhibitor rcc patient
treat vegf inhibitor melanoma patient receiv opdivo cb-
achiev orr cr pr dcr combin
treatment nsclc patient rcc patient achiev stabl diseas
rcc patient receiv checkpoint inhibitor achiev stabl diseas
rcc patient treat vegf inhibitor achiev dcr initi
toler clinic activ promis small patient number durabl
respons continu evalu
celldex may bristol enter collabor celldex evalu
combin nivolumab varlilumab antibodi combo
evalu nsclc melanoma ovarian cancer schnc bristol paid
up-front develop cost share bristol first right negoti
out-licens varlilumab phase i/ii studi began januari favor
safeti data present earli efficaci portion phase ii trial on-going
interim result ovarian colorect cancer cohort present
total ovarian patient evalu demonstr orr
pr sd stratifi statu ovarian patient achiev orr
ovarian patient achiev orr overal ovarian
popul dcr patient increas tumor express
patient experienc increas til level total colorect
patient evalu demonstr dcr pr
clovi juli bristol announc collabor clovi evalu opdivo
rubraca rucaparib parpi sever tumor type decemb
initi phase ii trial evalu opdivo combin
either rubraca docetaxel enzalutamid treatment mcrpc estimate primari
complet februari june compani also initi phase
athena trial ovarian cancer evalu opdivo rubraca post platinum chemo
estimate primari complet decemb clovi conduct compani also
intend initi phase tnbc bristol conduct term collabor
disclos
compugen octob bristol announc collabor compugen
equiti invest evalu opdivo plu anti-pvrig solid
tumor compugen sponsor on-going phase trial evalu combo
nsclc ovarian breast endometri cancer futur combo may also pursu
bristol includ tigit plu anti-pvrig
swedish compani upfront/near-term mileston payment
addit development/regulatori mileston lead product
acquir phase i/ii mab target believ
complementari t-cell direct antibodi co-stimulatori molecul thu
potenti enhanc immun respons increas efficaci io therapi
cytomx may bristol enter collabor cytomx develop
novel therapi immune-oncolog target use cytomx probodi platform
probodi monoclon antibodi select activ cancer
microenviron focu activ tumor leav healthi tissu intact bristol
exclus ww right develop commerci four oncolog target
includ probodi pre-clin phase i/ii clinic trial initi decemb
non-fucosyl probodi may greater potenc pre-
clinic trial target select process complet decemb trigger
payment bristol paid up-front provid research fund pay
futur mileston payment target well royalti
futur sale march collabor expand includ eight
addit target six oncolog two non-oncolog bristol pay cytomx
up-front extens continu provid research fund may pay
mileston target well tier royalti futur sale
decemb phase i/ii first-in-human trial initi evalu
probodi alon combin opdivo solid tumor trial
intend enrol patient evalu safeti measur primari endpoint
estim primari complet juli
daiichi sankyo august bristol announc collabor daiichi
evalu opdivo plu metastat breast bladder cancer ds-
compos human antibodi attach novel topoisomeras
inhibitor dxd payload tetrapeptid linker design deliv enhanc cancer cell
destruct upon releas insid cell reduc system exposur
grant track design breast cancer patient fail
target therapi phase ib trial evalu opdivo breast
bladder cancer initi june intend enrol patient
estim primari endpoint complet dlt orr septemb
daiichi conduct studi licens azn may make
futur collabor uncertain
enterom novemb bristol announc collabor enterom
develop microbiome-deriv biomark drug target bioactiv
molecul develop potenti companion diagnost therapeut
cancer includ biomark specif bristol io portfolio bristol receiv exclus
right ip therapi pay enterom up-front provid fund
may pay futur unspecifi mileston payment royalti
februari bristol announc collabor evalu
cabometyx cabozantinib plu opdivo opdivo yervoy rcc bladder cancer
potenti tumor type cabometyx small molecul
tyrosin kinas inhibitor current approv tablet formul rcc
develop program co-fund phase trial rcc vs sutent
start juli primari complet septemb primari
endpoint phase trial rcc vs opdivo yervoy also initi
primari complet novemb
f-star alpha ltd octob bristol enter agreement exclus
option acquir f-star alpha ltd lead compound target
therapi evalu pre-clin studi breast gastric
cancer bristol make payment may total includ mileston
payment option right bristol respons conduct
fund develop option period exercis option acquir f-
star ltd base decis initi phase iib trial novemb f-star ltd
initi phase trial breast gastric solid tumor trial
list complet june patient enrol data disclos
clinic program advanc
prime march bristol sign agreement prime therapeut
develop commerci two immun checkpoint pathway agent
cabiralizumab antibodi bristol paid up-front pay
research fund acquir stock could
potenti pay mileston payment well tier royalti third
immun checkpoint agent ad collabor januari januari
research term extend one year march addit research
fund provid januari prime announc achiev
mileston first ind collabor antibodi
elect extend research term march provid addit fund
prime
cabiralizumab evalu solid tumor pigment villonodular
synov pvn pancreat cancer novemb phase data
cabiralizumab opdivo advanc solid tumor present
show earli efficaci signal heavili pretreat advanc pancreat cancer
patient evalu patient durabl clinic benefit seen patient
includ confirm pr mss patient microsatellit stabl kol view
data encourag respons pancreat cancer consid meaning
earli data phase i/ii studi pvn present show
evalu patient radiograph respons treat
cabiralizumab everi two week improv median ogilvie-harri composit
pain/funct score achiev respond non-respond
addit patient show evid shrink tumor data patient
still immatur cutoff date pancreat cancer phase ii studi
cabiralizumab nivolumab /- chemotherapi initi decemb
estim enrol patient estim primari complet
infin novemb bristol enter collabor infin
pharmaceut evalu opdivo oral inhibitor solid
tumor preclin data suggest may enhanc effect revers
tumor resist checkpoint inhibitor on-going phase i/ib studi solid tumor
initi decemb includ patient nsclc melanoma
head neck cancer whose tumor show initi develop resist immun
checkpoint therapi septemb studi expand includ
nave tnbc patient interim data studi present
evalu patient demonstr diseas control pr sd
analysi peripher blood pair tumor biopsi indic combin
opdivo reduc immun suppress induc immun activ
trae grade common rash pruritu
nausea anemia increas alt increas ast pyrexia present
treat patient treatment-rel death
novemb compani announc trial combo would
initi urotheli cancer infin run phase ii io nave
advanc urotheli cancer patient progress platinum-bas chemo
primari endpoint orr assess overal subset patient
vari level mdsc myeloid deriv suppressor cell
janssen biotech juli bristol announc collabor janssen biotech
evalu opdivo phase ii studi antigen-present
therapeut base live attenu double-delet ladd listeria monocytogen
strain engin induc immun respons nsclc tumor jnj-
current phase lung cancer data combin
present efficaci modest patient grade
includ case treatment-rel fatal pneumon develop halt
januari collabor announc evalu opdivo darzalex
daratumumab mm solid tumor phase i/ii trial mm
first initi septemb recruit delay stall readout trial
current recruit updat may estim primari
complet june phase ib/ii solid tumor list activ
recruit estim primari complet august
lilli januari bristol enter collabor conduct phase i/ii
trial opdivo galunisertib beta inhibitor advanc solid tumor
includ glioblastoma hepatocellular carcinoma nsclc lilli conduct
md anderson cancer center octob bristol md anderson cancer center
form collabor evalu opdivo yervoy three earli stage compound
potenti treatment acut chronic leukemia hematolog
malign collabor launch phase phase ii trial aml
cll cml md mf
novarti octob bristol announc collabor novarti evalu
opdivo zykadia ceritinib c-met egfr phase i/ii studi
nsclc novarti conduct studi june collabor
expand includ phase i/ii studi mekinist trametinib opdivo mekinist
opdivo yervoy mismatch repair bristol conduct studi
psioxu juli bristol announc exclus clinic collabor
psioxu evalu lead compound enadenotucirev inject unarm oncolyt
adenoviru combin opdivo treat variou late-stag tumor
enadenotucirev design immun stimul effect may enhanc
efficaci opdivo bristol psioxu share develop cost bristol
exclus right combin first right futur commerci
enadenotucirev decemb agreement expand includ right
pre-clin arm oncolyt viru bristol pay psioxu up-front
potenti mileston plu royalti sale
seattl genet januari bristol announc collabor seattl
genet evalu opdivo adcetri brentuximab vedotin antibodi drug
conjug hematolog malign one phase i/ii trial pursu
r/r hl conduct data evalu patient present
ishl octob orr cr pr os
data evalu patient part studi
present decemb patient part receiv four
cycl stagger dose day adcetri mg/kg day opdivo mg/kg cycl
concurr thereaft wherea patient part receiv four cycl
concurr adcetri nivo day evalu patient orr cr
estim rate
second trial pursu r/r b-cell t-cell nhl includ dlbcl conduct
bristol interim data present decemb evalu
patient orr cr pr stabl diseas
progress diseas common grade neutropenia
peripher neuropathi common grade
neutropenia thrombocytopenia decreas neutrophil count
hypersensit diarrhea maculopapular rash treatment-rel
report patient
data first trial r/r nhl present show orr
includ cr safeti profil accept infus reaction
common se june updat data patient present
show orr includ cr also june collabor
expand includ phase trial opdivo adcetri vs adcetri alon r/r
transplant inelig chl phase initi june
evalu primari outcom estim primari complet date
follow-up data phase i/ii opdivo adcetri studi present ishl
octob decemb median follow-up month
evalu patient orr cr pr neither mpf mo
reach howev os rate rate
patient treat opdivo adcetri cr rate opdivo adcetri
combin therapi r/r chl nearli doubl rate report either agent
individu suggest possibl complementari mechan opdivo
adcetri pathway strong phase ii result bode well pivot
phase evalu opdivo adcetri vs adcetri alon r/r chl
patient inelig asct trial initi may estim
primari complet novemb assess primari endpoint
tari decemb bristol announc collabor tari biomed
evalu opdivo combin gemri phase ib studi mibc
muscl invas bladder cancer patient schedul radial cystectomi taris-
system design continu releas gemcitabin bladder
day bristol made undisclos equiti invest tari
transgen april bristol announc collabor transgen
evalu opdivo therapeut vaccin design gener immun
respons express tumor nsclc single-arm phase ii trial
opdivo chemo nsclc patient low/neg express
plan transgen conduct trial data expect
vedanta bioscienc decemb bristol announc collabor
vedanta bioscienc evalu opdivo microbiome-bas io agent
metastat cancer pre-clin model shown induc cell
potenti immun system attack tumor cell amplifi effect anti-
therapi financi term disclos bristol intend make equiti
invest vedanta
april bristol acquir privat held flexu bioscienc up-front
potenti mileston payment bristol acquir full right
flexu lead pre-clin molecul small molecul inhibitor
phase bristol also acquir flexu ido/tdo discoveri program includ
ido-select tdo-select ido/tdo dual compound howev full
develop program subsequ size evalu ido
move forward phase ii biomark select popul includ bladder
cancer preclin data present demonstr
restor t-cell prolifer co-cultur cell human cancer cell
co-cultur cell allogen dendrit cell
nm also demonstr favor pharmacodynam mous tumor
well human tumor xenograft nude mice
bristol-my squibb develop yervoy ipilimumab treatment metastat
melanoma yervoy mab neg regul t-cell activ
yervoy demonstr first meaning advanc metastat melanoma year
spark renew interest immune-oncolog drug first approv fda
unresect metastat melanoma label subsequ
expand includ adjuv patient undergon complet resect
combin opdivo juli label expand includ patient
year older unresect metastat melanoma eu label
similarli expand januari
physician consult believ yervoy mechan action limit
inhibit broader immun activ effect suggest array side
effect physician expert view kinet respons uniqu differ
chemo mani respons delay patient may experi pseudo-
progress worsen tumor size follow tumor shrinkag given
limit use recist criteria defin progress new set criteria monitor
efficaci develop irrc immune-rel respons criterion
given data show benefit blockad vs
key driver yervoy growth adopt
opdivo yervoy combin melanoma tumor recent
posit result opdivo yervoy nsclc repres signific
upsid potenti first line patient advanc melanoma physician
consult believ opdivo yervoy treatment choic bristol estim
new metastat melanoma patient receiv combo
also note commun physician may prefer monotherapi
avoid combo addit toxic combo may need
yervoy price per infus annual cap estim
yervoy sale
data ipilimumab second-lin phase studi present
subsequ publish new england journal medicin total patient
unresect stage iv melanoma whose diseas progress
receiv therapi metastat diseas randomli assign ipilimumab plu
peptid vaccin ipilimumab alon alon ipilimumab dose
mg/kg four treatment induct elig patient
receiv subsequ re-induct therapi median overal surviv
month ipilimumab plu ipilimumab alon month
alon differ arm report
grade immune-rel occur patient ipilimumab vs
patient treat common includ diarrhea nausea fatigu
death relat studi drug seven associ
immune-rel advers event use corticosteroid improv time resolut
author conclud ipilimumab without peptid vaccin
compar alon improv overal surviv patient previous
treat metastat melanoma also note advers event sever
long-last revers appropri treatment
trial design evalu safeti efficaci
ipilimumab add-on dtic dacarbazin untreat unresect stage iii/iv
melanoma studi met primari endpoint mo ipilimumab dtic
month vs month dtic alon median durat respons
month combo vs month dtic alon mpf month vs
dtic alon long-term data show percent surviv
superior combo surviv
vs dtic jco public note
ipilimumab surviv data report studi approxim longer
histor expect patient stage iv melanoma kaplan-mei surviv curv
also show clear plateau around mark suggest long-term surviv
benefit subset patient
total number event compar across arm
combo vs dtic alon vs dermatolog gi event
common addit patient dtic experienc increas alt/ast
compar dtic alon grade alt/ast event
dtic arm compar dtic alon
ipilimumab approv stage adjuv melanoma late approv
base phase studi patient stage resect melanoma
random ipilimumab placebo ipilimumab patient dose mg/kg
first four dose subsequ year diseas
recurrence/unaccept toxic compar placebo ipilimumab reduc risk
recurr death recurr free surviv
ipilimumab vs placebo importantli ipilimumab also show
reduct risk death os ipilimumab
vs placebo
grade ipilimumab vs placebo immune-rel grade
ipilimumab vs placebo ipilimumab group patient
die due immune-rel advers event physician expert view data
impress also note side effect signific mg/kg dose
approv adjuv set vs metastat set
reserv experienc center
howev juli bristol announc primari endpoint recurrence-fre
surviv rf met plan interim look phase studi opdivo vs
yervoy treatment patient resect stage iiib/c stage iv melanoma
opdivo significantli improv rf versu yervoy
demonstr sustain rf benefit month opdivo receiv fda approv
indic decemb
result studi ipilimumab combin nivolumab
present publish nejm phase ib dose-rang studi enrol
highli refractori advanc melanoma patient treat either concurr
sequenti dose respons rate patient treat concurr
dose vs patient treat sequenti dose respons
deep patient concurr dose tumor reduct
patient sequenti dose updat os show one- two-
year os across patient confirm cr rate increas
respons consist across braf mutat statu express
level grade treatment-rel concurrent-regimen vs
sequenti regimen
phase ii studi combin nivo ipi vs ipi monotherapi
treatment advanc melanoma orr primari endpoint secondari endpoint
interim result present simultan publish nejm
april braf wild-typ patient orr cr
opdivo yervoy combin vs yervoy alon cr
median braf wild-typ patient reach time assess
combin treatment significantli decreas risk progress brafmut
patient mpf month combin vs
month yervoy septemb fda grant acceler condit
approv opdivo yervoy treatment braf wild-typ patient
unresect metastat melanoma base phase ii
april present updat updat
result summar
remark efficaci came cost increas toxic higher frequenc
grade vs higher discontinu rate vs
howev immun relat resolv immunosuppress
therapi patient discontinu therapi continu experi
respons think physician like initi combo therapi mani
patient given higher chanc achiev cr subsequ switch
monotherapi toxic difficult toler
june data phase nivolumab plu ipilimumab
vs either agent alon first line melanoma present trial enrol
patient show mpf month combo month nivo
month ipi combin demonstr reduct risk progress vs
ipi vs ipi respons rate combo
nivo ipi complet respons combo nivo
alon ipi alon updat publish new england journal medicin
septemb show mo month alon month nivo
alon reach nivo ipi combo overal surviv rate year
nivo combo
burden hr wt patient
treatment-rel combo nivo ipi treatment-
relat ae lead discontinu diarrhea
importantli patient discontinu nivo ipi due treatment relat
achiev respons discuss conclud nivo ipi pois
becom new standard care first line melanoma combin shown
clearli superior either agent alon howev superior opdivo yervoy vs
opdivo observ patient
physician consult believ physician use opdivo monotherapi
patient combo provid addit efficaci increas toxic howev
combin shown substanti benefit like
patient prescrib combo also believ use combin
commun may limit given doctor concern yervoy
toxic also view opdivo therapeut equival keytruda albeit
keytruda may slight advantag monotherapi given dose vs opdivo
septemb bristol announc rcc stop
earli plan interim analysi combin opdivo yervoy
demonstr superior efficaci meet os co-primari endpoint data impress
given earli separ os curv clearli superior rr improv safeti profil
april combin opdivo yervoy approv rcc base
data publish nejm long-term follow-up
publish lancet oncolog full data review opdivo
section summar chart
june data present opdivo yervoy
treatment patient dna mismatch repair/microsatellit instabl high
metastat colorect cancer dmmr/msi-h februari fda grant
breakthrough therapi design opdivo yervoy adult dmmr/msi-h
post treatment fluoropyrimidin oxaliplatin irinotecan foi time
fda also accept sbla combin treatment grant prioriti
review combin grant acceler approv dmmr/msi-h juli
octob present updat
demonstr durabl benefit opdivo yervoy combin
median follow-up month neither median os median reach
cutoff data summar chart
bristol-my squibb jointli develop elotuzumab antibodi
target glycoprotein highli express myeloma nk cell
normal tissu target tumor immun cell elotuzumab
simultan tag tumor cell recognit activ nk-depend kill
novemb fda approv emplic mm use combin
revlimid dexamethason base phase trial eu approv
grant may june bristol announc phase ii trial
emplic pomalidomid low dose dexamethason r/r mm met
 approv combin receiv novemb eu
approv august
eloqu uptak could increas studi front line combin
novel therapi like pomalidomid pomalyst dexamethason possibl io
success comparison data jnj darzalex daratumumab
revlimid/ dexamethason data key benefit daratumumab close
month consid separ curv set high bar type
benefit unpreced daratumumab singl agent activ superior
elotuzumab physician consult express enthusiasm daratumumab
backbon agent combin therapi elotuzumab daratumumab
view safe elotuzumab advantag administr daratumumab
induct dose take close whole day clinic howev subq formul
phase appear promis data file expect
bristol record profit pay royalti ex abbvi estim
emplic sale record bristol
interim look present show patient
treat elotuzumab plu lenalidomid dexamethason experienc
reduct risk diseas progress death compar len/dex alon
elotuzumab contain arm compar
len/dex alon arm orr elotuzumab contain
arm compar len/dex alon arm importantli limit
addit toxic elotuzumab arm grade hematolog non-
hematolog compar two arm median
lower report phase ii month vs month howev
differ explain refractori popul enrol studi
patient enrol qualifi high-risk use imwg
criteria compar phase ii trial
data subsequ updat confirm emplic reduc risk
progress death importantli emplic
combin delay need subsequ myeloma therapi median one
year compar lenalidomid dexamethason alon data also show
favor statist signific os benefit updat
safeti toler data consist previou data well balanc across
arm grade neutropenia e-ld ld anemia e-ld
ld fatigu e-ld ld diarrhea e-ld
show durabl clinic relev improv minim
increment toxic compar data benefit appear modestli
narrow present note possibl due high degre censor
hr overal significantli impact
studi open label note dropout rate
reason progress higher ld group may suggest
patient awar experiment arm like drop
remain one limit studi
four-year follow-up data present june show sustain reduct risk
progression/death vs revlimid/dex consult believ emplic
clean safeti profil solid efficaci allow ad nearli
immunomodulatori drug proteasom inhibitor-bas backbon
june interim result phase ii trial present
annual meet evalu treatment pomalidomid
low-dos dexamethason without emplic r/r mm primari
endpoint time assess patient receiv emplic pomalidomid
achiev reduct risk diseas progress vs treatment
pomalidomide-alon primari endpoint mpf month
combin vs month pomalidomide-alon benefit slightli
better patient prior line treatment vs line treatment
orr combin vs pomalidomide-alon os still
immatur time assess show posit trend
emplic pomalidomid combin ci first
random trial emplic pomalidomid r/r mm show clinic meaning
benefit pomalidomide-alon combin offer altern
treatment option patient fail lenalidomid prior proteosom
sprycel dasatinib dual src/abl kinas inhibitor first approv
chronic phase cp ph philadelphia chromosom cml ph
case patient resistant/intoler prior therapi includ gleevec
sprycel approv use ph cml patient cp august
label updat includ safeti efficaci data cp ph cml
year safeti efficaci data cp ph cml novemb approv
use sprycel children ph cml chronic phase eu approv
indic grant juli decemb sprycel approv
 use newli diagnos pediatr ph eu approv indic
receiv februari use solid tumor explor
investigator-sponsor research sprycel fail prostat breast cancer
phase ii trial nsclc close due lack response/enrol
januari sprycel substanc patent exp revok
european patent offic bristol appeal earli februari epo upheld
origin rule patent invalid gener dasatinib expect
avail eu ye launch start earli sprycel
gener eu approv cml cml account sale
enforc label use vari countri sprycel face eu competit
 sprycel cover four orang book patent three expir
one expir patent litig bristol apotex
settl septemb allow apotex launch gener forecast
sprycel sale flat
phase head-to-head studi versu gleevec newli diagnos cml patient
present data head-to-head studi line cml
demonstr sprycel superior gleevec decemb novarti file
first-lin indic tasigna portend impress result head-
to-head studi tasigna versu gleevec de novo cml patient sprycel data
outshin tasigna set sprycel may conveni given
sprycel gleevectasigna cytogenet respons mo comparisonsmajor molecular respons mo comparison post hoc analysi valu adjust multipl comparison sprycel vs gleevectasigna vs gleevecsprycel gleevectasigna advers eventfluid vs gleevectasigna vs gleevec
cowen compani clinicaltri gov
bristol provid updat data dasis trial show
five year sprycel patient achiev major molecular respons mmr vs
gleevec also five year sprycel patient remain treatment vs
gleevec addit sprycel patient achiev vs
gleevec five year sprycel gleevec os
sprycel gleevec advers reaction occur greater sprycel
musculoskelet pain rash nausea grade event hematolog lab
abnorm occur first year
orencia abatacept t-cell co-stimul launch
eu iv formul ra patient fail one dmard
april label broaden includ patient moder
sever ra anti-tnf methotrex failur august fda
includ clinic data label support orencia use patient ra two
year durat less orencia use monotherapi combin
tradit non-biolog dmard orencia also approv treatment
juvenil idiopath arthriti fda approv subcutan formul eu
approv receiv sq formul account eu sale
 sale juli bristol launch new orencia sq auto-
injector devic self-administr juli orencia approv
psoriat arthriti adult iv sq administr orencia
given concomitantli anti-tnf recommend use
biolog ra therapi eu approv grant august
bristol seri patent cover orencia method use patent term
extens grant one composition-of-matt patent extend
term patent method use patent ra expir eu
substanc patent includ spc data protect expir
method patent expir sq patent expir expir
eu novemb momenta/mylan announc orencia biosimilar
meet primari pk endpoint phase studi manag
tasigna versu gleevecsprycel versu gleevecbosutinib versu endpointr mmr month degre elimin cella carri bcr-abl protein marrow best confirm complet cytogenet respons ccyr monthscytogen respons rate monthsdosetasigna bidsprycel qdbosutinib state increas decreas qdgleevec qdgleevec start increas decreas
anticip gener forecast orencia sale
pivot phase studi astraea intern double-blind multicent
phase studi evalu abatacept treatment vs placebo patient
present patient random receiv subcutan sc
abatacept mg weekli placebo week treatment abatacept
demonstr superior efficaci patient achiev respons week
vs placebo maintain efficaci one year regardless
previou treatment tumor necrosi factor inhibitor tnfi
patient studi prior exposur tnfi abatacept demonstr favor
toler similar safeti profil placebo
data crohn scleroderma ankylos spondyl recent lupu nephriti
disappoint orencia still pursu polyangi phase
nulojix belatacept optim fusion protein differ orencia
amino acid treatment transplant reject june fda
approv nulojix prevent acut reject adult patient kidney
transplant drug approv use immunosuppress specif
basiliximab mycophenol mofetil corticosteroid forecast nulojix sale
ptld post-transpl lymphoprolif disord result unregul
product b-cell immunosuppress increas likelihood
develop mutat within b-cell popul domin mutat may prevail
result malign similar burkitt lymphoma nulojix label
particularli warn ptld predominantli involv patient
expos epstein-barr viru risk greater ebv seroneg
patient given ebv carri donat organ recommend
patient test ebv receiv nulojix test show
alreadi expos viru physician consult concern
high acut reject ptld rate versu cyclosporin benefit
benefit-ext studi acut reject rate associ graft failur
howev transplant consult believ acut reject manag
case physician moder impress belatacept benefit
glomerular filtrat rate gfr kidney function improv gfr translat
long-term graft surviv although yet demonstr howev one
physician consult believ belatacept compar tacrolimu vs
cylcosporin gfr benefit may seen tacrolimu use wide
 shown less detriment kidney function cyclosporin
anoth box warn nulojix label well label
immunosuppress warn increas risk seriou infect progress
multifoc leukoencepholopathi pml cancer use nulojix liver
transplant recommend administr belatacept associ
higher rate graft loss death compar tacrolimu
oral inhibitor evalu psoriasi sle ibd
inhibit impact interferon pathway phase ii data moder
sever psoriasi present octob show pasi
respons spga respons three highest dose
safeti profil appear accept discontinu rate
seen three highest dose vs placebo phase trial psoriasi
recent start co-
primari endpoint trial spga pasi week primari
complet juli
inhibitor evalu indic phase ii trial enrol
crohn lupu psoriat arthriti ulcer coliti potenti differenti factor
includ select inhibit efficaci par biolog psoriasi base
ph ii data safeti profil differenti jak estim sale bms-
novemb bristol enter agreement biotech ab
give bristol exclus right acquir lead asset galectin-
inhibitor idiopath pulmonari fibrosi ipf total payment could potenti
reach includ mileston payment bristol exercis option acquir
later day follow complet phase ib trial bristol
nitto denko novemb bristol sign exclus ww licens agreement
nitto denko develop commerci sirna molecul
target heat shock protein vitamin contain formul
collagen specif chaperon regul collagen synthesi secret
prevent collagen deposit enabl resolut exist fibrosi
lead compound current phase ib studi treatment
advanc liver fibrosi due nash hepat fda grant track
statu indic bristol also option exclus ww right
sirna molecul lung fibrosi organ fibrosi bristol paid nitto
up-front unspecifi mileston payment royalti
eliqui apixaban select oral direct factor xa inhibitor offer good oral
bioavail food effect half-lif hour low peak trough ratio
organ toxic rais lft seen anim toxic studi apixaban excret
predominantli via liver also kidney may requir monitor
superior bleed profil compar warfarin
late fda ema approv eliqui stroke system embol
prevent atrial fibril spaf patient nonvalvular atrial fibril
nvaf strong label reflect data aristotl averro trial
addit indic ad includ dvt prevent fda approv march
eu approv may treatment dvt pe prevent recurr
dvt pe follow initi therapi approv eu juli august
eliqui continu build momentum share august show
increas share month bristol believ still share captur
warfarin addit portola andexxa andexanet alfa antidot eliqui
approv may posit chmp receiv march provid
support broader use eliqui eliqui composit matter patent
expir eliqui partner bristol book sale pay profit
forecast eliqui sale
eliqui approv spaf strong label includ superior
warfarin stroke prevent bleed caus death label includ
box black warn cite higher incid thromboembol event patient
discontinu eliqui xarelto label also black box warn event
patient discontinu eliqui reason patholog bleed coverag
anoth anticoagul recommend eu label contain refer
increas event stop therapi box warn xarelto
eliqui pradaxa demonstr superior warfarin reduc stroke
patient nonvalvular atrial fibril xarelto savaysa edoxaban
demonstr non-inferior eliqui novel anticoagul demonstr
reduct major clinic relev non-major bleed rel warfarin
novel anticoagul improv overal mortal given superior clinic
profil price eliqui believ compel reason prescrib
anticoagul spaf
rang trial spaf ac vte treatment prevent support approv
indic trial summari chart provid
eliqui current approv decreas risk stroke/system embol
patient nonvalvular atrial fibril nvaf decemb phase iv
anticoagul vitamin antagonist nvaf patient expect undergo
cardiovers short-term anti-coagul patient receiv eliqui usual
care prior cardiovers day post-convers primari efficaci
endpoint occurr acut stroke system embol all-caus death
trial complet end top-lin result present esc
eliqui bmy/pf pradaxa bi xarelto fda indicationspafspafspaf dvt treatment preventionsuperior warfarin spaf yesyesnosuperior bleed warfarinyesnono mortal benefityesnonoblack box warningincreas event rate patient discontinu eliquisnaincreas event rate patient discontinu xarleto increas risk spinal/epidur hematoma spinal settingapixaban dosecomparatornumb patientsstatussurg vte replac surgeri bidlovenox show replac surgeri bidlovenox result major vte clinic relev bleed replac surgeri bidlovenox enoxaparin prevent symptomatic/asymptomat dvt pe all-caus death differ bleed clinic relev bleed compar enoxaparin alonemed prophylaxisaverroesstrok prevent atrial fibril bid bid select patientsaspirin warfarin inelig earli efficacyaristotlestrok prevent atrial fibril vka efficaci bleed profil compar warfarin statist signific mortal benefit demonstratedadoptacut medic bidlovenox show differenti mace recent safeti path forwardvt treatmentamplifyacut bid day bid monthslovenox standard careamplify-extlong-term treatment vs placebo reductionof recurr vte/al caus death
popul eliqui heparin/vka
stroke system emboli eliqui vs stroke one hemorrhag five
ischem system emboli soc group safeti analysi popul
eliqui heparin/vka numer fewer major
bleed event apixaban vs soc numer fewer clinic
relev non-major bleed event apixaban vs soc howev
import note eliqui increas risk bleed caus seriou
potenti fatal bleed death report eliqui group one due
acut alcohol hepat prior dose one due complic relat
perfor colon one death also report soc group eman
find support use apixaban patient afib undergo cardiovers
approxim afib patient also concomit coronari arteri diseas
may result ac requir pci oral anticoagul dual antiplatelet
therapi help reduc risk stroke recurr ischem event respect
combin lead increas risk bleed march announc
result phase iv augustu trial evalu eliqui vs vka nvaf patient
recent ac and/or undergo pci patient receiv inhibitor
without aspirin proport major clinic relev non-major bleed
month significantli lower eliqui vs vka
met superior threshold primari endpoint pre-defin secondari outcom
patient receiv inhibitor without aspirin lower rate death
hospit eliqui vs vka vs howev eliqui
vka demonstr similar rate death ischem event vs
result add safeti profil eliqui broaden use
april bristol announc collabor janssen develop
factor xia inhibitor program includ lead candid move
phase ii trial secondari stroke prevent primari complet may
bristol receiv undisclos up-front payment development/regulatori
mileston compani share development/commerci cost global
decemb bristol acquir privat held cardioxyl pharmaceut
lead asset novel intraven pro-drug phase ii
adhf acut decompens heart failur releas nitroxyl
demonstr earli clinic trial improv heart muscl contraction/
relax without relat increas heart rate and/or oxygen consumpt bristol
pay up-front near-term mileston long-
term develop sale mileston phase ii safeti efficaci studi
expect primari complet june data yet present list ct gov
activ recruit inform potenti registr start
bristol final agreement uniqur exclus access
gene therapi platform includ uniqur chf program focus
restor heart abil synthes calcium sensor regul
heart function agreement allow collabor ten target includ
may extend diseas beyond cv diseas uniqur respons
discoveri manufactur bristol lead develop regulatori activ
respons cost sole respons commerci
futur product bristol paid approxim up-front includ
close target select equiti invest uniqur
bristol acquir addit ownership posit year end
potenti pay uniqur mileston payment
apiec product well royalti sale
reyataz atazanavir proteas inhibitor fda approv novemb part
combin therapi treatment-nav patient ritonavir-boost reyataz offer
improv dose two capsul daili virtual impact lipid major
advantag kaletra januari bristol receiv fda approv
evotaz reyataz cobicistat boost agent gilead fix dose combin
juli evotaz receiv eu approv howev competit pressur led
declin share trend merck isentress viiv tivicay integras inhibitor
approv treatment-na hiv patient competitor front-lin reyataz
basic patent expir june march eu countri
forecast reyataz sale
competit pressur new hiv agent launch gener
dampen outlook atripla/sustiva franchis sale forecast
baraclud entecavir approv march induc signific viral load reduct
compar lamivudin vs patient demonstr undetect hbv
dna two year shown resist four year therapi baraclud
ideal lamivudine-refractori patient due cross-resist specif
lamivudine-refractori patient experi virolog breakthrough four
year baraclud therapi separ baraclud preclin carcinogen data
remain sourc debat infecti diseas commun
septemb teva launch gener version two dose
baraclud use ex-u gener alreadi exist china howev brand baraclud
maintain preferenti placement china nation formulari gener
baraclud maintain modest growth china forecast baraclud sale
januari bristol final sale portion diabet collabor
astrazeneca regulatori launch sales-rel
payment receiv cash includ farxiga
approv januari japan approv march paid
total amylin azn paid enter collabor
elimin diabet franchis reduc bmi primari care footprint
enabl greater focu target specialti area novemb bristol
transfer futur royalti right onglyza farxiga royalti
pharma exchang addit tiered-bas royalti estim
bmi diabet royalti
cowen compani
ep risk industri averag exposur
revlimid signific
estim sale year prior patent expir
cowen compani thomson pharma compani data fda orang book
commentsww synthet saxagliptin dpp-iv inhibitor competit inferior label drive dapagliflozin inhibitor market eu assum continu post transact canadian pension board late continu post transact canadian pension board late onglyza/forxiga royalti chang start post transact royalti continu post transact canadian pension board late line lcompanydrugterritorypat date estim ww sale mm sale total salesestim sale mm non-u sale total salesestim non-u sale mm total salesep total estim sale year prior patent expir assum gener entri assum net margin
bristol new product portfolio domin three drug opdivo eliqui yervoy
agent top line primari driver new drug combin
estim sale potenti
new product could contribut increment ep
compani data cowen compani
commentsopdivo nivolumab antibodi numer datapoint upcom includ adjuv approv spaf dvt treatment prophylaxi market share patent expir ipilimumab monoclon ab melanoma tumor immun oncolog combin use drive file s/eu md pdufa beta thalassemia pdufa ph ii oral select file rm us/eu pdufa uc crohn initi via celg bcma car-t multipl myeloma file car-t ph data file r/r dlbcl ph ii r/r enasidenib r/r elotuzumab approv refractori multipl myeloma line data fedratinib highli select inhib myelofibrosi resist patient intoler jakafi approv eu file small molecul io target phase immunosci psoriasi small molecul phase biolog phase fibrot diseas small molecul phase io target biolog phase dual small molecul phase io target biolog phase btk immunosci small molecul phase manag fibrot diseas biolog phase iifactor xia small molecul cardiovascular phase iinitroxyl heart failur small molecul phase celgen pipelin opportunitiestot new net
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
current liabil work capit ex activ net incom depreci chang work capit adjust net activ capit acquisitions/divestitur purchas /sale secur activ net debt dividend share repurchas chang equival
compani data cowen compani estim
assumpt outputequ share outstand gross margin oper interest incom tax work free net cash base estim balanc sheetbmi dcf
approv mm r/r mm
w/poma dex file r/r mm
w/poma dexin jp piii mm
nivolumab approv
tumor type mani combo
hematolog malign solid
ipilimumab approv
rcc sever pii/piii mono combin
ido inhibitor combo nivolumab
dna methylas inhibitor
fedratinib inhibitor approv
thallasemia pdufa us file
combo opdivo
opdivo plu yervoy numer tumor
mono
combo w/ nivolumab solid tumor pii/iii
melanoma gastric
psa-target cancer immunotherapi
treatment asymptomat
minim symptomat mcrpc
celmod focus aml
agonist stimul interferon gene
malign fda chmp grant
orphan drug statu aml
factor xia inhibitor prevent
treatment major thrombot condit
total drug develop
marker count toward column total advanc phase
cowen compani
metabol lipid diabet
met primari endpoint nash
antagonist treatment idiopath
signal
abatacept supplement applic
iv sc-inject file ra jp mar-
piii primari sjogren vascul
wegen piii lupu nephriti fail
